November 27, 2014

Biotechnology

The Long Road

Nabi Biopharmaceuticals is in the homestretch as it works on two drugs designed to fight infections.

Barbara Miracle | 7/1/2005
While Scripps Florida has generated lots of buzz about the future of biotech in south Florida, one company is hoping that the future is now. Boca Raton-based Nabi Biopharmaceuticals is on the cutting edge of immune system research with several products in the final stages of clinical trials. "We're right at the crest of the wave," says Thomas McLain, chairman, CEO and president of Nabi.
BIOTECH FLORIDA
bioflorida.com

The website of the state's independent bioscience organization explains the various types of biotechnology applications and has a list of biotech companies in the state, monthly calendars of events and details of the group's annual fall conference.

Nabi's story illustrates the nature of the path a biotech company takes as it makes its way through research, development, clinical trials, the regulatory approval process and finally marketing. Launched in 1969, Nabi started out as a plasma-collection company. In the early 1990s, it shifted its focus to drugs for the immune system. One high-profile project was an immune therapy product designed to stop transmission of the HIV virus from mother to infant. After extensive clinical trials, the product was discontinued when studies showed that AZT drug therapy alone reduced the rate of mother-to-infant HIV transmissions to almost zero.

Today, Nabi focuses on bacterial infections that patients pick up in hospitals. McLain says that after a long period in which the mortality rate from these infections was only 5%, it is increasing because some infections are becoming resistant to antibiotics. The issue is attracting media attention in developed countries. In the recent British parliamentary elections, the opposition Conservative Party charged that the number of deaths from hospital infections was greater than the number of traffic deaths each year. In the U.S., the Centers for Disease Control reports that studies show between five and 10 infections for every 1,000 patient days in the hospital.

Nabi has two products in its pipeline designed to prevent infections and treat them in conjunction with antibiotics. StaphVAX, which the company has been working on for a decade, is in the final stages of phase III clinical trials -- the final research and development before gaining regulatory approval. Patients would be given StaphVAX seven to 10 days before entering the hospital for surgery, an IV line or other invasive procedure to protect them from infection. Earlier this year, Nabi applied to the European Medicines Agency for a license, and McLain says Nabi plans to submit its license application to the U.S. Food and Drug Administration by the end of 2005.

The second product, Altastaph, would be given to patients after they enter the hospital for immediate protection. It also would be used with antibiotics to treat patients who did pick up a bacterial infection. Altastaph is going through phase I and II clinical trials.

An unrelated product in Nabi's pipeline is NicVAX, a vaccine to treat nicotine addiction.

"Florida has a lot going for it," says Nabi CEO Thomas McLain.

Funding much of this research is the cash from three products currently on the market: Nabi-HB, a plasma-based product that contains antibodies to the hepatitis B antigen; Aloprim, a drug for oncology patients who have elevated blood uric acid levels; and PhosLo, a drug to control high serum phosphorus levels in patients with end-stage renal failure. The company projects revenue between $137 million and $142 million for 2005, with $88 million to $91 million coming from biopharmaceutical products and the remainder from plasma and related products.

McLain is upbeat about Nabi and the future of biotech in Florida. "Florida has a lot going for it," he says, noting the state's universities and pool of entrepreneurs. But as a reminder that biotech research and development successes don't happen overnight, he notes, "To bring a drug forward, it's a 12- or 15-year process."

Tags: Southeast

Digital Access

DIRECT DIGITAL ACCESS
Add digital to your current subscription, purchase a single ditgital issue, or start a new subscription to Florida Trend.

TABLE OF CONTENTS
An overview of the features and articles in this month's issue of Florida Trend.

ACCESS THIS ISSUE »

Florida Business News

Florida Trend Video Pick

What your doctor won’t disclose
What your doctor won’t disclose

Wouldn’t you want to know if your doctor was a paid spokesman for a drug company? Or held personal beliefs incompatible with the treatment you want? Right now, in the US at least, your doctor simply doesn’t have to tell you about that. 

Earlier Videos | Viewpoints@FloridaTrend

Ballot Box

What's your favorite thing about the Thanksgiving break?

  • Spending time with family & friends
  • Shopping & deals
  • Eating!!
  • Watching sports
  • What break? I'm busy working!

See Results

Ballot Box
Subscribe